Eliem Therapeutics Inc

NASDAQ ELYM

Data sourced from

and

Download Data

Eliem Therapeutics Inc Long-Term Investments 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending December 31, 2022: -100.00%

Eliem Therapeutics Inc Long-Term Investments 1 year YoY Change (%) is -100.00% for the Trailing 12 Months (TTM) ending December 31, 2022. Long-Term Investments are investments that are not expected to be converted into cash within one year. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Eliem Therapeutics Inc Long-Term Investments for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 25.91 M.

NASDAQ: ELYM

Eliem Therapeutics Inc

CEO	Mr. Robert W. Azelby M.B.A.
IPO Date	Aug. 10, 2021
Location	United States
Headquarters	23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees	9
Sector	Healthcare
Industry	Biotechnology

Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Key trends